Literature DB >> 17034134

Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles.

Muthukaman Nagarajan1, Andrew Morrell, Alexandra Ioanoviciu, Smitha Antony, Glenda Kohlhagen, Keli Agama, Melinda Hollingshead, Yves Pommier, Mark Cushman.   

Abstract

In connection with an ongoing investigation of indenoisoquinoline topoisomerase I (Top1) inhibitors as potential therapeutic agents, the pharmacophore possessing di(methoxy) and methylenedioxy substituents was held constant, and new derivatives were synthesized with nitrogen heterocycles appended to the lactam side chain. Compounds were evaluated for Top1 inhibition and for cytotoxicity in the National Cancer Institute's human cancer cell screen. Some of the more potent derivatives were also screened for in vivo activity in a hollow fiber assay. The results of these studies indicate that lactam substituents possessing nitrogen heterocycles can provide highly cytotoxic compounds with potent Top1 inhibition. Molecular modeling of these compounds in complex with DNA and Top1 suggests that some of the lactam substituents are capable of interacting with the DNA base pairs above and below the site of intercalation and/or with Top1 amino acid residues, resulting in increased biological activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17034134      PMCID: PMC2526314          DOI: 10.1021/jm060564z

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  20 in total

1.  Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors.

Authors:  M Cushman; M Jayaraman; J A Vroman; A K Fukunaga; B M Fox; G Kohlhagen; D Strumberg; Y Pommier
Journal:  J Med Chem       Date:  2000-10-05       Impact factor: 7.446

2.  A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.

Authors:  Christophe Marchand; Smitha Antony; Kurt W Kohn; Mark Cushman; Alexandra Ioanoviciu; Bart L Staker; Alex B Burgin; Lance Stewart; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2006-02       Impact factor: 6.261

3.  Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.

Authors:  Bart L Staker; Michael D Feese; Mark Cushman; Yves Pommier; David Zembower; Lance Stewart; Alex B Burgin
Journal:  J Med Chem       Date:  2005-04-07       Impact factor: 7.446

4.  Synthesis of benz[d]indeno[1,2-b]pyran-5,11-diones: versatile intermediates for the design and synthesis of topoisomerase I inhibitors.

Authors:  Andrew Morrell; Smitha Antony; Glenda Kohlhagen; Yves Pommier; Mark Cushman
Journal:  Bioorg Med Chem Lett       Date:  2006-01-25       Impact factor: 2.823

5.  Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis.

Authors:  Alexandra Ioanoviciu; Smitha Antony; Yves Pommier; Bart L Staker; Lance Stewart; Mark Cushman
Journal:  J Med Chem       Date:  2005-07-28       Impact factor: 7.446

Review 6.  Non-camptothecin DNA topoisomerase I inhibitors in cancer therapy.

Authors:  Ling-Hua Meng; Zhi-Yong Liao; Yves Pommier
Journal:  Curr Top Med Chem       Date:  2003       Impact factor: 3.295

7.  Design, synthesis, and biological evaluation of indenoisoquinoline topoisomerase I inhibitors featuring polyamine side chains on the lactam nitrogen.

Authors:  Muthukaman Nagarajan; Xiangshu Xiao; Smitha Antony; Glenda Kohlhagen; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2003-12-18       Impact factor: 7.446

8.  Design, synthesis, and biological evaluation of cytotoxic 11-aminoalkenylindenoisoquinoline and 11-diaminoalkenylindenoisoquinoline topoisomerase I inhibitors.

Authors:  Xiangshu Xiao; Smitha Antony; Glenda Kohlhagen; Yves Pommier; Mark Cushman
Journal:  Bioorg Med Chem       Date:  2004-10-01       Impact factor: 3.641

9.  Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.

Authors:  Brian M Fox; Xiangshu Xiao; Smitha Antony; Glenda Kohlhagen; Yves Pommier; Bart L Staker; Lance Stewart; Mark Cushman
Journal:  J Med Chem       Date:  2003-07-17       Impact factor: 7.446

10.  Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors.

Authors:  Andrew Morrell; Smitha Antony; Glenda Kohlhagen; Yves Pommier; Mark Cushman
Journal:  Bioorg Med Chem Lett       Date:  2004-07-16       Impact factor: 2.823

View more
  30 in total

1.  Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.

Authors:  Dhriti Sooryakumar; Thomas S Dexheimer; Beverly A Teicher; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2011-06-02       Impact factor: 6.261

2.  Design, synthesis, and evaluation of dibenzo[c,h][1,6]naphthyridines as topoisomerase I inhibitors and potential anticancer agents.

Authors:  Evgeny Kiselev; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2010-11-23       Impact factor: 7.446

3.  Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore.

Authors:  Daniel E Beck; Monica Abdelmalak; Wei Lv; P V Narasimha Reddy; Gabrielle S Tender; Elizaveta O'Neill; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2015-04-24       Impact factor: 7.446

4.  7-azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents.

Authors:  Evgeny Kiselev; Sean DeGuire; Andrew Morrell; Keli Agama; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2011-08-08       Impact factor: 7.446

5.  Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity.

Authors:  Katherine E Peterson; Maris A Cinelli; Andrew E Morrell; Akhil Mehta; Thomas S Dexheimer; Keli Agama; Smitha Antony; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2011-06-28       Impact factor: 7.446

6.  Synthesis and biological evaluation of 6-substituted indolizinoquinolinediones as catalytic DNA topoisomerase I inhibitors.

Authors:  Le-Mao Yu; Xiao-Ru Zhang; Xiao-Bing Li; Yuan Yang; Hong-Yu Wei; Xi-Xin He; Lian-Quan Gu; Zhi-Shu Huang; Yves Pommier; Lin-Kun An
Journal:  Eur J Med Chem       Date:  2015-07-08       Impact factor: 6.514

7.  Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships.

Authors:  Maris A Cinelli; Brenda Cordero; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  Bioorg Med Chem       Date:  2009-09-06       Impact factor: 3.641

8.  Activity of indenoisoquinolines against African trypanosomes.

Authors:  Rahul P Bakshi; Dongpei Sang; Andrew Morrell; Mark Cushman; Theresa A Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

9.  HPLC method development, validation, and impurity characterization of a potent antitumor indenoisoquinoline, LMP776 (NSC 725776).

Authors:  Jennie Wang; Mingtao Liu; Chun Yang; Xiaogang Wu; Euphemia Wang; Paul Liu
Journal:  J Pharm Biomed Anal       Date:  2016-02-27       Impact factor: 3.935

10.  Mechanistic studies of the modulation of cleavage activity of topoisomerase I by DNA adducts of mono- and bi-functional PtII complexes.

Authors:  Jaroslav Malina; Oldrich Vrana; Viktor Brabec
Journal:  Nucleic Acids Res       Date:  2009-07-09       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.